Oncology companies develop therapies, diagnostics and technologies that support the detection, monitoring and treatment of cancer. The sector is one of the largest and most active areas of biotechnology and pharmaceutical innovation.
This category includes companies working on:
Browse 291 UK oncology companies below.
Next-generation CAR T-cell therapies for solid tumours
ImmunoKey is a seed-stage biotechnology company developing CAR T-cell therapies designed to overcome the barriers limiting efficacy in solid tumours. Its proprietary platform enables multi-antigen targeting while minimising off-tumour toxicity, supported by complementary technologies to enhance T-cell persistence and…
Oncolytic virus immunotherapies engineered to destroy solid tumours
Bioarchitech is a preclinical-stage biotechnology company developing oncolytic virus-based immunotherapies for the treatment of common solid tumours. The company engineers vaccinia virus to encode antibody-like immunotherapy molecules within the viral genome, enabling localised delivery of immune-activating payloads…
Clinical-stage antibody-drug conjugate specialist targeting solid tumours
Pheon Therapeutics is a clinical-stage biotechnology company developing a pipeline of antibody-drug conjugates for the treatment of solid tumours. The company combines monoclonal antibodies with proprietary cytotoxic payloads and linker technologies, taking a target-specific approach to optimising each construct for…
Intranasal anti-CD3 immunotherapy for neuroinflammatory diseases
Tiziana Life Sciences is a clinical-stage biopharmaceutical company developing immunomodulatory therapies for neurological and inflammatory diseases. Its lead candidate, intranasal foralumab, is a fully human anti-CD3 monoclonal antibody designed to modulate T-cell activity through nasal administration. The 48-patient…
Macrophage-targeted therapeutics for oncology, neurological and fibrotic diseases
Macomics is a University of Edinburgh spin-out developing macrophage-targeted medicines across oncology, neurodegenerative, inflammatory and fibrotic diseases. Its ENIGMAC drug discovery platform combines human macrophage and microglia models derived from induced pluripotent stem cells, gene editing and…
Antigen modulation therapies for cancer and autoimmune disease
Grey Wolf Therapeutics is a clinical-stage biotechnology company developing small molecule inhibitors of endoplasmic reticulum aminopeptidases (ERAP1 and ERAP2) to modulate antigen presentation on cell surfaces. In oncology, this approach enhances tumour visibility to the immune system; in autoimmunity, it aims to…
Small molecule regulators of mitochondrial transfer for age related disease
Nascent Therapeutics is a biotechnology company developing small molecule therapies that regulate mitochondrial transfer between cells. The company's discovery platform identifies compounds that promote the uptake of healthy mitochondria into damaged cells, or block cancer cells from taking mitochondria from…
Clinical genomic decision support software for rare disease and oncology
Congenica is a clinical genomic interpretation platform spun out of the Wellcome Sanger Institute. Its software supports variant analysis and clinical reporting across rare disease, oncology and infectious disease, integrating whole genome sequencing data with phenotypic information to generate actionable diagnostic…
ADC oncology company developing novel spliceosome-modulating payloads
Akari Therapeutics is a clinical-stage biopharma company developing next-generation bi-functional antibody-drug conjugates for cancer treatment. Its proprietary ADC platform centres on PH1, a novel spliceosome-modulating small molecule payload designed to disrupt RNA splicing in tumour cells and activate anti-tumour…
Multimodal engineered T-cell therapies for treatment-refractory solid cancers
Alceus Bio is a biotechnology company developing next-generation engineered T-cell therapies for solid tumours. Its platform uses generative AI and synthetic biology to design therapeutic proteins that patient-derived immune cells are programmed to express and deliver in situ, targeting intracellular disease drivers…
CAR-T and bispecific antibody therapies for blood cancers
Hemogenyx Pharmaceuticals is a clinical-stage biopharmaceutical company developing targeted therapies for haematological malignancies and autoimmune diseases. Its lead asset, HG-CT-1, is a third-generation anti-FLT3 CAR-T cell therapy for relapsed and refractory acute myeloid leukaemia, currently in a Phase 1…
Breath-based volatile organic compound test for multi-cancer detection
SpiraCheck is a biotechnology company developing a non-invasive breath test for the early detection of gastrointestinal cancers. Patients exhale into a collection device; the sample is analysed in the laboratory by mass spectrometry to quantify volatile organic compounds, and a patented algorithm interprets the…
DNA damage response platform targeting hard-to-treat solid tumours
Artios Pharma is a clinical-stage biopharmaceutical company developing small molecule therapeutics that target DNA damage response pathways in cancer cells. The company's pipeline includes alnodesertib, an ATR inhibitor advancing toward late-stage development in ATM-deficient solid tumours, and ART6043, a DNA…
Global biopharma with UK R&D centre on the Wirral Peninsula
Bristol-Myers Squibb (BMS) is a global biopharmaceutical company with a long-established UK R&D site at Moreton on the Wirral Peninsula and its UK and Ireland commercial headquarters in Uxbridge. The Moreton facility, expanded in 2025, conducts chemistry, manufacturing and control activities supporting pharmaceutical…
Allogeneic neutrophil cell therapy platform for solid tumours
LIfT BioSciences is a biotechnology company developing a first-in-class allogeneic neutrophil immunotherapy for the treatment of solid tumours. Its platform produces Immuno-Modulatory Alpha Neutrophils (IMANs) from donor haematopoietic or induced pluripotent stem cells using a proprietary enhancement process. IMANs…
Precision medicine platform matching cancer patients to optimal therapies
Pathway Bio is a precision oncology company developing a functional platform to predict treatment response in individual cancer patients. The platform combines multiomic tumour profiling, AI-driven modelling, and ex vivo microcancer technology to screen therapies against a biological avatar of the patient's own tumour…
Engineered iPSC-derived exosomes for tissue-targeted drug delivery
Excellio Labs is a biotech developing engineered exosome platforms for targeted drug delivery. The technology exploits the inherent tissue-specificity of iPSC-derived extracellular vesicles, which are further surface-modified to create precision drug carriers capable of delivering nucleic acids, proteins, and small…
Clinical-stage rare disease biotech acquiring deprioritised pharma assets
Mereo BioPharma is a clinical-stage biopharmaceutical company focused on developing treatments for rare diseases. Founded in 2015, its business model centres on acquiring clinical-stage programmes deprioritised by large pharmaceutical companies and advancing them through further development. Lead programmes include…
Small molecule protein degraders targeting oncology and CNS disease
Kesmalea Therapeutics is a biotechnology company developing oral small molecule therapeutics that modulate protein homeostasis through targeted protein degradation and stabilisation. The company's platform is designed to convert the potency of protein degrader approaches into orally bioavailable, CNS-penetrant small…
Molecular imaging and targeted cancer therapy agents
Edinburgh Molecular Imaging is a biopharmaceutical company developing molecular imaging and targeted therapeutic agents for cancer and other diseases. Its research includes fluorescent peptide probes for image-guided surgery and radiolabelled compounds directed at c-Met, a receptor expressed in several tumour types.…